ATCC Expands Leadership Team to Provide Vision and Growth Strategy

Published on :

ATCC, the world’s premier biological materials management and standards organization, today announced the promotion of Rebecca Bradford to the position of Vice President, Government Programs in the ATCC Federal Solutions (AFS) business unit, and Linda Johnson to Vice President, Licensing and Intellectual Property Management. Both positions will continue to bring leadership and vision to ATCC’s growth strategy.

NRx Pharmaceuticals Announces the Appointment of Stephen Willard, Chief Executive Officer and Director

Published on :

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP): (“NRx Pharmaceuticals”, or the “Company”), a clinical-stage biopharmaceutical company, today announced the appointment of Stephen Willard, as its Chief Executive Officer (“CEO”) and a member of the Company’s Board of Directors. The Company’s interim CEO, Robert Besthof, will continue to support the Company and return to his roles as Head of Operations and Chief Commercial Officer.  

In Conversation: Stacy Rollinger, VP of Human Resources at NextCure

Published on :

NextCure recently brought on a new Vice President of Human Resources, Stacy Rollinger, SPHR, to lead the human resources function and drive talent acquisition activities. We caught up with Rollinger to discuss her career journey, NXTC’s workplace culture, the company’s talent acquisition approach, and its future hiring goals.

Jessica Meng Joins Delfi Diagnostics as Chief Commercial Officer

Published on :

Jessica Meng Joins Delfi Diagnostics as Chief Commercial Officer
NEWS PROVIDED BY
Delfi Diagnostics
Jul 12, 2022, 08:00 ET
SHARE THIS ARTICLE
BALTIMORE, July 12, 2022 /PRNewswire/ — Delfi Diagnostics, Inc., a pioneering developer of a new class of high-performance, accessible liquid biopsy tests for early cancer detection and monitoring, has hired Jessica Meng as the company’s first Chief Commercial Officer.
Jessica Meng
“Jessica is a strategic leader who has scaled commercial organizations in therapeutics and diagnostics and knows what it takes to commercialize successful oncology products,” said Delfi Founder and CEO Victor Velculescu, MD, PhD. “We are excited to have her leadership as we prepare to introduce the first products on the Delfi platform.”
Jessica is a proven commercial leader with a 20+ year track record in healthcare and extensive product launch leadership. She most recently led the Women’s Health Division of Myovant Sciences as General Manager and Vice President of Sales & Marketing, where she played a key role in the formation of the co-promotion partnership with Pfizer. Prior to Myovant, Jessica was Vice President of Marketing for Veracyte, launching multiple genomic diagnostic products in oncology and pulmonology and helping to grow the commercial organization’s headcount from 50…

5 Questions with Jose Jimenez, Vice President and Director of Life Sciences at Gilbane Building Company

Published on :

Jose supports Gilbane’s life sciences clients across the Greater Philadelphia, New Jersey, Baltimore, and Washington, DC metro areas with speed to patient goals, and a focus on safely delivering quality facilities. His 22 years in the construction industry include directing major capital programs involving new building construction, building additions, and renovations of active cGMP manufacturing and research facilities ranging between $5 million and over $250 million per project.

My Career Journey: Cristina Rexach, Senior Talent Consultant at Workforce Genetics

Published on :

Cristina Rexach recently joined Workforce Genetics (WFGX) as a Senior Talent Consultant. Prior to joining WFGX, Cristina had a successful run as a Global MedTech Recruiter with the Mullings Group, a talent acquisition firm serving the medical device industry. She brings more than a decade of experience in the life sciences industry to her new role. Cristina had a highly successful career in healthcare management and sales before transitioning to the talent side of the industry.  

INOVIO Appoints Dr. Michael Sumner, MB BS, MBA as Chief Medical Officer

Published on :

INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help protect people from infectious diseases and treat people with cancer and HPV-associated diseases, today announced the appointment of Dr. Michael Sumner, MB BS, MBA, as Chief Medical Officer (CMO). Dr. Sumner will oversee INOVIO’s clinical-stage pipeline of DNA medicines, global clinical development, clinical operations and biostatistics efforts, as well as regulatory affairs, pharmacovigilance and medical affairs. He will serve on the company’s executive leadership team and will report to INOVIO’s President and Chief Executive Officer, Dr. Jacqueline Shea.

5 Questions with Jason Bosiacki, Associate Director, Manufacturing Operations at NextCure

Published on :

Jason received his bachelor’s degree in biology with a minor in chemistry from Frostburg State University. He has been in the biotech industry for 12 years, having spent most of that time in R&D, primarily immunology and in the manufacturing of biologics, making monoclonal antibodies and fusions proteins.